Cedars-Sinai Heart Institute, Los Angeles, California 90048, USA.
J Am Coll Cardiol. 2013 Mar 12;61(10):1108-19. doi: 10.1016/j.jacc.2012.10.052. Epub 2013 Jan 23.
We sought to characterize the immunologic profile of allogeneic cardiospheres, which are 3-dimensional, self-assembling, cardiac-derived microtissues, and to evaluate their safety and efficacy in repairing ischemic heart tissue.
Intramyocardial injection of autologous cardiospheres ameliorates remodeling and improves global function in infarcted myocardium. It is as yet unknown whether allogeneic cardiospheres are similarly effective without eliciting deleterious immune reactions.
We expanded cardiospheres from male Wistar Kyoto rat hearts and injected them surgically in the peri-infarct zone of Wistar Kyoto (syngeneic group, n = 28) and Brown Norway female rats (allogeneic group, n = 29). Female rats from both strains (n = 37) injected with normal saline served as controls.
In vitro, cardiospheres expressed a low immunogenic profile and inhibited proliferation of alloreactive T cells. In vivo, cell engraftment was similar in the syngeneic and allogeneic groups 1 week and 3 weeks after transplantation. Reductions in scar size and scar collagen content and increases in viable mass in the risk region were accompanied by improvements in left ventricular function and attenuation of left ventricle remodeling that were sustained during 6 months of follow up. Transplantation of allogeneic cardiospheres increased tissue expression of the regenerative growth factors vascular endothelial growth factor, hepatocyte growth factor, and insulin-like growth factor-1, stimulating angiogenesis. Syngeneic and allogeneic cardiospheres attenuated the inflammatory response observed histologically in the peri-infarct region.
Allogeneic cardiospheres increase viable myocardium, decrease scar, improve function, and attenuate adverse remodeling in the infarcted rat heart, without deleterious immunological sequelae. These observations lay the groundwork for developing cardiospheres as a novel off-the-shelf microtissue product for myocardial regeneration.
我们旨在描述异体心脏球体的免疫特征,心脏球体是一种 3 维自组装的心脏衍生微组织,并评估其在修复缺血性心脏组织中的安全性和有效性。
心肌内注射自体心脏球体可改善梗死心肌的重构并改善整体功能。目前尚不清楚异体心脏球体是否同样有效而不会引起有害的免疫反应。
我们从雄性 Wistar Kyoto 大鼠心脏中扩增心脏球体,并将其手术注射到 Wistar Kyoto(同基因组,n=28)和 Brown Norway 雌性大鼠(同种异体组,n=29)的梗死周边区。接受生理盐水注射的两种品系的雌性大鼠(n=37)作为对照组。
在体外,心脏球体表达了低免疫原性特征,并抑制同种反应性 T 细胞的增殖。在体内,移植后 1 周和 3 周,同基因和同种异体组的细胞植入相似。在风险区域,减少疤痕大小和疤痕胶原含量以及增加存活组织质量,伴随着左心室功能的改善和左心室重构的减弱,这种改善在 6 个月的随访期间得以维持。同种异体心脏球体移植增加了组织中再生生长因子血管内皮生长因子、肝细胞生长因子和胰岛素样生长因子-1 的表达,刺激了血管生成。同基因和同种异体心脏球体减弱了在梗死周边区观察到的组织学炎症反应。
同种异体心脏球体增加存活心肌,减少疤痕,改善功能,并减弱梗死大鼠心脏的不良重构,而没有有害的免疫后果。这些观察结果为开发心脏球体作为一种新颖的现成微组织产品用于心肌再生奠定了基础。